Related Experiment Video
Updated: Dec 14, 2025

Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Periprosthetic Joint Infection: A Review of Antibiotic Treatment
Ryan Miller1, Carlos A Higuera, Janet Wu
11Departments of Infectious Disease (R.M. and M.B.), Pharmacy (J.W.), and Orthopedic Surgery (A.K. and N.S.P.), Cleveland Clinic, Cleveland, Ohio 2Department of Orthopedic Surgery, Cleveland Clinic, Weston, Florida.
Abstract:
A team approach among orthopaedic surgeons, infectious disease specialists, and patients is of paramount importance when treating periprosthetic joint infections (PJIs). Treatment usually includes various surgical approaches along with antibiotic treatment. Antibiotic selection requires a multifactorial decision that depends on the organism that is identified, its antibiotic-resistance profile, the extent of the infection, and factors associated with the host. Antibiotic duration is dependent on surgical intervention and the type of organism. Typically, patients are treated for 6 weeks after debridement, antibiotics, and implant retention (DAIR) and for 4 to 6 weeks after single-stage and 2-stage revision arthroplasty. Levofloxacin in combination with rifampin has shown favorable outcomes for Staphylococcus PJI treatment. Quinolones have excellent bioavailability and bone and joint concentrations. Ciprofloxacin can be used for sensitive gram-negative infections. Evidence is emerging that supports the use of oral antibiotics after 7 days of intravenous antibiotics for the treatment of PJI. Although this should be considered carefully, it can potentially alleviate the burden on patients and caregivers, with fewer intravenous lines and the potential for fewer complications.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis III: Medical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Endocarditis IV: Nursing Management
Tonsillitis II: Management
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

